Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Markus Rückert, Guillaume Azarias, Mamta Garg, Ceri Bygrave, Hannah Belcher, Clare Hague, Kristina Bardenheuer, Wout Vekemans, Morten Salomo, Blanca Gros Otero, Nolen Perualila, Michel Van Speybroeck, Joris Diels, Vladimir Maisnar, Ivan Špička, Roman Hájek

Blood (2024) 144 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2024-201692

Published: 2024

Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Rafael Fonseca, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Seina Lee, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Winfried Alsdorf, Margherita Ursi

Blood (2024) 144 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2024-201583

Published: 2024

Journal Articles

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Nieves Lopez-Muñoz, Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Seina Lee, Teresa Hernando, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Urvi A. Shah

Blood (2024) 144 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2024-201568

Published: 2024

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Blood (2024) 144 (Supplement 1): 7088.

https://doi.org/10.1182/blood-2024-205189

Published: 2024

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Seina Lee, Nikoletta Lendvai, Nitin Patel, José Sanchez-Pina

Blood (2024) 144 (Supplement 1): 7084.

https://doi.org/10.1182/blood-2024-201596

Published: 2024

Journal Articles

Efficacy of Carvykti in CARTITUDE-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Winfried Alsdorf, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Carlos Fernández de Larrea, Margherita Ursi

Blood (2023) 142 (Supplement 1): 6901.

https://doi.org/10.1182/blood-2023-182175

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz

Blood (2023) 142 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2023-182141

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noemi Puig, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, José María Sanchez-Pina, Serena Rocchi

Blood (2023) 142 (Supplement 1): 6910.

https://doi.org/10.1182/blood-2023-182164

Published: 2023

Journal Articles

Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting

Jose Angel Hernandez-Rivas, Pier Luigi Zinzani, Mats Jerkeman, Malalatiana Be Harvel, Suzy Van Sanden, Joris Diels, Asad Husain, Christoph Tapprich, Sanjay Deshpande, Steven Le Gouill, Martin Dreyling

Blood (2022) 140 (Supplement 1): 3648–3650.

https://doi.org/10.1182/blood-2022-158259

Published: 2022

Journal Articles

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Roman Hajek, Henrik Sliwka, Martin Stork, Ivan Spicka, Tomas Jelinek, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Jan Soukup, Nolen Joy Perualila, Joris Diels, Michel van Speybroeck, Nichola Erler-Yates, João Mendes, Kai Strobel, Sébastien Wischlen, Maximilian Merz

Blood (2022) 140 (Supplement 1): 7200–7202.

https://doi.org/10.1182/blood-2022-159401

Published: 2022

Journal Articles

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Michel Delforge, Marie-Christiane Vekemans, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Danielle Strens, Sandra Van Hoorenbeeck, Evelien J Moorkens, Joris Diels, Francesca Ghilotti, Sander Dalhuisen, Sophie Vandervennet

Blood (2021) 138 (Supplement 1): 4075.

https://doi.org/10.1182/blood-2021-146250

Published: 2021

Journal Articles

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

Blood (2021) 138 (Supplement 1): 550.

https://doi.org/10.1182/blood-2021-146200

Published: 2021

Journal Articles

Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases

Michael Doubek, Mudr. Lukas Smolej, Martin Šimkovič, Anna Panovska, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Emmanuel Bachy, Lucile Baseggio, Emmanuelle Ferrant, Joris Diels, Jedelyn Cabrieto, Lasse Nielsen, Gilles Salles

Blood (2021) 138 (Supplement 1): 4679.

https://doi.org/10.1182/blood-2021-147927

Published: 2021

Journal Articles

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Irina Demmer, Susanne Huschens, Dietrich Potthoff, Jörg Tomeczkowski, Christian Englisch, Pushpike Thilakarathne, Joris Diels, Shaji K. Kumar, MD, Brian GM Durie, MD, Lewin Eisele

Blood (2018) 132 (Supplement 1): 3541.

https://doi.org/10.1182/blood-2018-99-116884

Published: 2018

Journal Articles

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clementine Sarkozy, MD, Alexandra Traverse-Glehen, MD PhD, Emmanuel Bachy, Lionel Karlin, MD, Hervé Ghesquières, MD PhD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Gilles Salles, MD

Blood (2017) 130 (Supplement 1): 2770.

https://doi.org/10.1182/blood.V130.Suppl_1.2770.2770

Published: 2017

Journal Articles

Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases

Gilles Salles, MD PhD, Lukas Smolej, MD PhD, Emmanuel Bachy, Lucile Baseggio, MD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Wafae Iraqi, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Martin Spacek, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Michael Doubek, MD PhD

Blood (2017) 130 (Supplement 1): 5342.

https://doi.org/10.1182/blood.V130.Suppl_1.5342.5342

Published: 2017

Journal Articles

Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients

Blood (2016) 128 (22): 3332.

https://doi.org/10.1182/blood.V128.22.3332.3332

Published: 2016

Journal Articles

Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma

Shaji K. Kumar, MD, Brian G M Durie, Zhuo Su, Joris Diels, PhD, Brian Hutton, Annette Lam, Ito Tetsuro

Blood (2016) 128 (22): 4517.

https://doi.org/10.1182/blood.V128.22.4517.4517

Published: 2016

Journal Articles

Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE TM and RESONATE-2 TM with the French Lyon-Sud Database

Gilles A. Salles, Lucile Baseggio, PharmD, PhD, Emmanuel Bachy, MD PhD, Clementine Sarkozy, MD, Herve Ghesquieres, MD PhD, Joris Diels, PhD, Hervé Besson, PhD, Finlay MacDougall, BA, Ruben Hermans, PhD MSc, Nollaig Healy, PhD, Jamie Garside, MSc, Wafae Iraqi, PharmD, PhD, Evelyne Callet-Bauchu, MD PhD

Blood (2016) 128 (22): 2039.

https://doi.org/10.1182/blood.V128.22.2039.2039

Published: 2016

Journal Articles

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Peter Hillmen, MB, ChB, PhD, Graeme Fraser, MDFRCPC, Jeffrey Jones, MD MPH, Simon Rule, MD, Susan O'Brien, MD, Marie Sarah Dilhuydy, MD, Ulrich Jaeger, MD, Sebastian Grosicki, MD PhD, Florence Cymbalista, MD PhD, Steven Sun, PhD, Joi Ninomoto, PharmD, Michelle Mahler, MD, Mei Cheng, PhD, Joris Diels, Fong Clow, ScD, Mariya Salman, PhD, Danelle F. James, MD MAS, Angela Howes, PhD, Asher Chanan-Khan, MD

Blood (2015) 126 (23): 2944.

https://doi.org/10.1182/blood.V126.23.2944.2944

Published: 2015

NARROW

Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Efficacy of Carvykti in CARTITUDE-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Elotuzumab, Isatuximab, and Selinexor-Based Regimens in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases

Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients

Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma

Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE TM and RESONATE-2 TM with the French Lyon-Sud Database

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only